Literature DB >> 28509196

Acquired Fanconi syndrome due to long-term adefovir administration in a patient with IgG-kappa monoclonal gammopathy and kappa Bence-Jones protein.

Shuzo Kaneko1, Yoshiyuki Hatakeyama2, Yusuke Tsukamoto2.   

Abstract

A 77-year-old man was admitted to our hospital for a right femoral neck fracture. He had been prescribed lamivudine for chronic hepatitis B infection for 11 years, and adefovir was added 5 years ago. After hospitalization, a right femoral head prosthesis was performed successfully, but an unknown hypokalemia was revealed. Hypophosphatemia, hypouricemia, glucosuria, and panaminoaciduria were also revealed, and multiple microfractures were detected by bone scintigraphy. We diagnosed him as 'osteomalacia associated with Fanconi syndrome,' which was likely due to the adefovir. Moreover, a monoclonal IgG-kappa and a kappa Bence-Jones protein were detected in his serum and urine, respectively. We switched from adefovir plus lamivudine to entecavir and started calcitriol. His excessive urinary β2-microglobulin excretion and glucosuria had decreased dramatically at 10 weeks after the modification of drugs; those of the phosphate, uric acid and total protein, however, continued. Renal biopsy specimens obtained at 10 weeks after discontinuation of adefovir revealed focal tubular atrophic changes with/without inflammatory cells, which were predominantly observed next to glomeruli. Kappa-dominant staining was not observed in either glomeruli or tubules with immunostaining by the enzyme-labeled antibody method. Electron microscopy revealed neither crystalline structures in the cytoplasm of proximal tubules nor electron-dense deposits. Because of the remarkable proportional reduction of other urinary protein fractions, urinary M-peak appeared 26 weeks after discontinuation of adefovir, but the net amounts of the fraction decreased gradually.

Entities:  

Keywords:  Adefovir; Fanconi syndrome; Monoclonal gammopathy

Year:  2014        PMID: 28509196      PMCID: PMC5411566          DOI: 10.1007/s13730-014-0115-4

Source DB:  PubMed          Journal:  CEN Case Rep        ISSN: 2192-4449


  15 in total

1.  Incidental finding of monoclonal gammopathy in blood donors: a follow-up study.

Authors:  Massimo La Raja; Monica Barcobello; Nicola Bet; Paolo Dolfini; Marina Florean; Federica Tomasella; Vincenzo De Angelis; Luca Mascaretti
Journal:  Blood Transfus       Date:  2012-03-28       Impact factor: 3.443

2.  Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir.

Authors:  Tomoki Imaoka; Hiroyuki Kusuhara; Masashi Adachi; John D Schuetz; Kenji Takeuchi; Yuichi Sugiyama
Journal:  Mol Pharmacol       Date:  2006-11-16       Impact factor: 4.436

3.  Plasma cell dyscrasia causing light chain tubulopathy without Fanconi syndrome.

Authors:  Matthew R Elliott; Cherise Cortese; Alvaro Moreno-Aspitia; Jamie P Dwyer
Journal:  Am J Kidney Dis       Date:  2009-10-21       Impact factor: 8.860

4.  Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial.

Authors:  J Kahn; S Lagakos; M Wulfsohn; D Cherng; M Miller; J Cherrington; D Hardy; G Beall; R Cooper; R Murphy; N Basgoz; E Ng; S Deeks; D Winslow; J J Toole; D Coakley
Journal:  JAMA       Date:  1999 Dec 22-29       Impact factor: 56.272

5.  Adefovir nephrotoxicity: possible role of mitochondrial DNA depletion.

Authors:  N Tanji; K Tanji; N Kambham; G S Markowitz; A Bell; V D D'agati
Journal:  Hum Pathol       Date:  2001-07       Impact factor: 3.466

6.  Acquired fanconi syndrome with osteomalacia secondary to monoclonal gammopathy of undetermined significance.

Authors:  Toru Hashimoto; Kimika Arakawa; Yuko Ohta; Takaichi Suehiro; Noriko Uesugi; Masaru Nakayama; Takuya Tsuchihashi
Journal:  Intern Med       Date:  2007-03-01       Impact factor: 1.271

7.  The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1.

Authors:  T Cihlar; D C Lin; J B Pritchard; M D Fuller; D B Mendel; D H Sweet
Journal:  Mol Pharmacol       Date:  1999-09       Impact factor: 4.436

8.  Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies.

Authors:  Hassane Izzedine; Jean Sebastien Hulot; Vincent Launay-Vacher; Patrick Marcellini; Stephanos J Hadziyannis; Graham Currie; Carol L Brosgart; Chris Westland; Sarah Arterbrun; Gilbert Deray
Journal:  Kidney Int       Date:  2004-09       Impact factor: 10.612

9.  Renal dysfunction and hypophosphatemia during long-term lamivudine plus adefovir dipivoxil therapy in patients with chronic hepatitis B.

Authors:  Mio Tanaka; Fumitaka Suzuki; Yuya Seko; Tasuku Hara; Yusuke Kawamura; Hitomi Sezaki; Tetsuya Hosaka; Norio Akuta; Masahiro Kobayashi; Yoshiyuki Suzuki; Satoshi Saitoh; Yasuji Arase; Kenji Ikeda; Mariko Kobayashi; Hiromitsu Kumada
Journal:  J Gastroenterol       Date:  2013-03-26       Impact factor: 7.527

10.  Kinetic analysis of the interaction between the diphosphate of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, ddCTP, AZTTP, and FIAUTP with human DNA polymerases beta and gamma.

Authors:  J M Cherrington; S J Allen; B H McKee; M S Chen
Journal:  Biochem Pharmacol       Date:  1994-11-16       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.